Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Tolerability of ENX-104 in Healthy Participants
NCT07472361Phase 1Completed
- Sponsor
- Engrail Therapeutics
- Start
- Feb 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ENX-104 (3 arms), sponsored by Engrail Therapeutics. Primary endpoint: Plasma Concentration of ENX-104. Started Feb 2026; status: completed.
02
Drugs
ENX-104
Beyond the preview
Go deeper on NCT07472361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472361.